GLP-1 medications now come in three formats: injectable pens, oral pills (FDA-approved), and compounded injectables from telehealth providers. The price and efficacy profile differ significantly across formats. Here's whether the convenience of a pill is worth the premium — or if it's actually cheaper.
Format-by-Format Price Comparison
| Format | Product | Monthly Cost | Weight Loss | Convenience |
|---|---|---|---|---|
| Oral pill | Foundayo (orforglipron) | $149-299 | ~11-12% | Any time, no food rules |
| Oral pill | Wegovy tablet (sema 25mg) | $149-349 | ~14-15% | Morning, empty stomach |
| Oral pill | Rybelsus (sema 14mg) | $149-349 | ~7% (diabetes) | Morning, 30min before food |
| Injectable pen | Wegovy (sema 2.4mg) | $199-349 | ~14.9% | Weekly injection |
| Injectable pen | Wegovy HD (sema 7.2mg) | $399 | ~16-18% | Weekly injection |
| Injectable pen | Zepbound (tirz 15mg) | $299-449 | ~20.2% | Weekly injection |
| Compounded inj. | GobyMeds (sema) | $99 | ~14.9%* | Weekly injection |
| Compounded inj. | GobyMeds (tirz) | $133 | ~20.2%* | Weekly injection |
| Compounded inj. | Embody (sema) | $149-299 | ~14.9%* | Weekly injection |
* Compounded medications contain the same active ingredient but have not been studied in clinical trials. Weight loss figures extrapolated from brand-name trial data.
The Convenience Premium
Oral GLP-1s eliminate the biggest barrier to treatment: needles. Many patients who are candidates for GLP-1 therapy avoid it specifically because of injection aversion. The arrival of convenient oral options (especially Foundayo, which has no food or timing restrictions) expands the addressable market significantly.
But convenience comes at a cost-per-pound-lost premium. The SURMOUNT-5 trial showed tirzepatide produces 20.2% weight loss vs semaglutide's 13.7% at 72 weeks. Foundayo's clinical trials showed approximately 11-12% weight loss — meaningful, but 35-40% less than injectable tirzepatide. If you calculate cost per percentage point of weight loss:
| Product | 12-Mo Cost | Est. Weight Loss | Cost per 1% Loss |
|---|---|---|---|
| GobyMeds sema | $1,188 | ~14.9% | $80 |
| GobyMeds tirz | $1,596 | ~20.2% | $79 |
| Foundayo | $2,388-3,588 | ~11-12% | $200-325 |
| Wegovy oral | $2,388-4,188 | ~14-15% | $160-300 |
| Wegovy injection | $3,588-4,188 | ~14.9% | $241-281 |
| Zepbound injection | $3,588-5,388 | ~20.2% | $178-267 |
When the Pill Is the Better Buy
The oral format makes financial sense when: you have commercial insurance that covers Foundayo or Wegovy tablet ($25/month with savings card — cheaper than any compounded option), you value convenience over maximum weight loss, you're needle-averse and wouldn't start injectable treatment at all, or you're on Medicare and can access the $50/month GLP-1 Bridge starting July 2026.
When Injectable Wins on Value
Injectable wins when: maximizing weight loss is the priority (20.2% with tirzepatide vs 11-12% with Foundayo), you're paying cash without insurance (compounded injectable at $99-130 beats oral at $149-299), or you're comfortable with weekly self-injection and want the strongest clinical evidence behind your medication.